Chemistry:Abelacimab
From HandWiki
Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of thrombosis,[1] under development by Anthos Therapeutics.
Mechanism of action
It is anti-factor XI antibody. The hope behind its developoment is that factor XI plays a bigger role in thrombosis (via the intrinsic/contact activation pathway) than hemostasis, so targeting it might reduce clotting risks without a corresponding increase in bleeding.[1] It has, indeed, shown overwhelming reduction in bleeding as compared to a direct oral anticoagulant (rivaroxaban) in patients with atrial fibrillation and a moderate-to-high risk of stroke.[2] Data is insufficient for drawing a conclusion on whether it increases or decreases stroke events as compared to rivaroxaban.[3]
See also
References
- ↑ 1.0 1.1 "Abelacimab for Prevention of Venous Thromboembolism". The New England Journal of Medicine 385 (7): 609–617. August 2021. doi:10.1056/NEJMoa2105872. PMID 34297496.
- ↑ "Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)". Business Wire. 18 September 2023. https://www.businesswire.com/news/home/20230918829025/en/Atrial-Fibrillation-Study-with-Abelacimab-Stopped-Early-by-the-Data-Monitoring-Committee-Due-to-an-Overwhelming-Reduction-in-Bleeding-as-Compared-to-a-DOAC-Direct-Oral-Anticoagulant.
- ↑ "Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation". The New England Journal of Medicine 392 (4): 361–371. January 2025. doi:10.1056/NEJMoa2406674. PMID 39842011.
 |  |
